EANS-News: Intercell starts an additional efficacy trial for its patch-based investigational Travelers´ Diarrhea Vaccine System in Asia

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Research & Development

Wien (euro adhoc) - _ » Phase II pilot efficacy trial - placebo
controlled field study to evaluate efficacy and enterotoxigenic E.
coli (ETEC) incidence of vaccinated European travelers to India »
Study designed to complement ongoing Phase III pivotal efficacy trial
of European travelers to Latin America - data expected to further
support licensure for prevention of enterotoxigenic E. coli (ETEC)
disease in travelers to multiple risk regions » Results expected
for end 2010

Vienna (Austria) / Gaithersburg (USA), January 4, 2010 - Intercell AG
(VSE:ICLL) announced today the start of a Phase II study in India as
part of its clinical development program for the investigational
Travelers´ Diarrhea (TD) Vaccine system. This placebo controlled
field study with vaccinated travelers from the EU to India will test
the efficacy of the Intercell TD vaccine. The primary objective of
this clinical trial is prevention of all moderate/severe diarrheal
cases in which LT, LT/ST or ST toxins (ETEC) are detected. The trial
will enroll approximately 800 travelers from the UK and Germany.

"The start of our next important TD trial underlines our dynamic
route to licensure and earliest possible commercialization with our
marketing partner GSK. Positive results from this study can greatly
support our expected product target profile" stated Thomas
Lingelbach, COO of Intercell AG and CEO of Intercell USA.

About the Travelers´ Diarrhea Vaccine System

The TD vaccine system is a combination of a patch containing the
dry-formulated LT (heat-labile toxin from E. coli, the vaccine
antigen) with a skin preparation system (SPS). The skin preparation
system (SPS) disrupts the stratum corneum of the skin and prepares
the skin for the antigen delivery. The antigen is dissolved from the
patch by transepidermal water loss and diffuses into the skin.
Activated Langerhans cells take the vaccine antigen to the draining
lymph nodes where the immune response is initiated. Currently, this
product candidate is undergoing pivotal Phase III testing in about
1,800 European travelers to Latin America. First results are expected
end 2010 / early 2011.

About Travelers´ Diarrhea

Diarrhea caused by enterotoxigenic E. coli (ETEC) is a disease
associated with significant morbidity in travelers to areas of the
world where fecal contamination of food and water is common.
Travelers' diarrhea is generally a 4-5 day illness with frequent
loose stools, usually associated with nausea, vomiting, abdominal
cramps, prostration, and dehydration. ETEC is also implicated in new
onsets of post-infectious irritable bowel syndrome (IBS), which
affects 10 to 20% of travelers who develop Travelers' Diarrhea.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market